Synthesis of [F-18]RGD-K5 by catalyzed [3+2] cycloaddition for imaging integrin alpha(v)beta(3) expression in vivo by Mirfeizi, Leila et al.
  
 University of Groningen
Synthesis of [F-18]RGD-K5 by catalyzed [3+2] cycloaddition for imaging integrin
alpha(v)beta(3) expression in vivo
Mirfeizi, Leila; Walsh, Joe; Kolb, Hartmuth; Campbell-Verduyn, Lachlan; Dierckx, Rudi A.;
Feringa, Ben L.; Elsinga, Philip H.; de Groot, Tjibbe; Sannen, Ivan; Bormans, Guy
Published in:
Nuclear Medicine and Biology
DOI:
10.1016/j.nucmedbio.2013.04.003
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2013
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Mirfeizi, L., Walsh, J., Kolb, H., Campbell-Verduyn, L., Dierckx, R. A., Feringa, B. L., ... Celen, S. (2013).
Synthesis of [F-18]RGD-K5 by catalyzed [3+2] cycloaddition for imaging integrin alpha(v)beta(3) expression
in vivo. Nuclear Medicine and Biology, 40(5), 710-716. https://doi.org/10.1016/j.nucmedbio.2013.04.003
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Nuclear Medicine and Biology 40 (2013) 710–716
Contents lists available at SciVerse ScienceDirect
Nuclear Medicine and Biology
j ourna l homepage: www.e lsev ie r .com/ locate /nucmedb ioSynthesis of [18F]RGD-K5 by catalyzed [3 + 2] cycloaddition for imaging integrin
αvβ3 expression in vivo
Leila Mirfeizi a,⁎, Joe Walsh b, Hartmuth Kolb b, Lachlan Campbell-Verduyn c, Rudi A. Dierckx a,
Ben L. Feringa c, Philip H. Elsinga a, Tjibbe de Groot e, Ivan Sannen d, Guy Bormans d, Soﬁe Celen d
a Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
b Siemens Molecular Imaging Biomarker Research, Culver City, CA, USA
c Stratingh Institute for Chemistry, University of Groningen, Groningen, The Netherlands
d Laboratory for Radiopharmacy, Faculty of Pharmaceutical Sciences, KU Leuven, Leuven, Belgium
e Department of Nuclear Medicine, U.Z. Gasthuisberg, KU Leuven, Leuven, Belgiuma b s t r a c ta r t i c l e i n f o⁎ Corresponding author.
E-mail addresses: l.mirfeizi@umcg.nl, smirfeizi@gma
0969-8051/$ – see front matter © 2013 Elsevier Inc. Al
http://dx.doi.org/10.1016/j.nucmedbio.2013.04.003Article history:
Received 24 October 2012
Received in revised form 11 March 2013
Accepted 1 April 2013In the last few years click chemistry reactions, and in particular copper-catalyzed cycloadditions have been
used extensively for the preparation of new bioconjugated molecules such as 18F-radiolabeled radiophar-
maceuticals for positron emission tomography (PET). This study is focused on the synthesis of the Siemens
imaging biomarker [18F]RGD-K5. This cyclic peptide contains an amino acid sequence which is a well known
binding motif for integrin αvβ3 involved in cellular adhesion to the extracellular matrix. We developed an
improved “click” chemistry method using Cu(I)-Monophos as catalyst to conjugate [18F]ﬂuoropentyne to the
RGD-azide precursor yielding [18F]RGD-K5. A comparison is made with the registered Siemens method with
respect to synthesis, puriﬁcation and quality control. [18F]RGD-K5was obtained after 75 min overall synthesis
time with an overall radiochemical yield of 35% (EOB). The radiochemical purity was N98% and the speciﬁc
radioactivity was 100–200 GBq/μmol at the EOS.il.com (Leila Mirfeizi).
l rights reserved.© 2013 Elsevier Inc. All rights reserved.1. Introduction
Integrins are heterodimeric (α − β) transmembrane proteins
expressed at the cell surface that are involved in cellular adhesion
to the extracellular matrix [1,2]. They stimulate vascular endothelial
cell migration and invasion, regulate their growth, survival and
differentiation and they serve as receptors for a variety of extracellular
matrix proteins including vitronectin, ﬁbronectin, ﬁbrinogen and
osteopontin. They are involved in many biological processes such as
angiogenesis, thrombosis, inﬂammation, osteoporosis and cancer,
playing a key role in many severe human diseases [3–5]. So far, 18 α
and 8 β subunits of integrins have been identiﬁed: they form 24
heterodimers, each with distinct ligand binding properties. Among
the integrin superfamily, αvβ3 and α5β1 integrins, targeted by the
RGD sequence, play a pivotal role in the formation of new blood
vessels in tissues (angiogenesis) [6–9]. αvβ3 and α5β1 integrins are
overexpressed on activated endothelial cells during physiological and
pathological angiogenesis [10].
Since αvβ3 integrin is expressed on tumor cells of various types
(melanoma, glioblastoma, ovarian and breast cancer) where it is in-
volved in the processes that govern metastasis, it represents anattractive target for cancer therapy and has stimulated ongoing
research to deﬁne high afﬁnity ligands [11,12].
RGD containing integrin ligands potentially have a large number
of medical applications ranging from noninvasive visualization of
integrin expression in vivo to the synthesis of functionalized bio-
materials. Over the past decade, a variety of radiolabeled cyclic pep-
tide antagonists with structures based on the RGD sequence have
been evaluated as integrin αvβ3-targeted radiotracers [13–15]. The
PET tracers [18F]Galacto-RGD, [18F]AH111585 and [18F]RGD-K5 are
currently under clinical investigation for visualization of integrinαvβ3
expression in cancer patients [16–21].
Due to its favourable β-energy and half-life, ﬂuorine-18 is themost
frequently used radionuclide in PET. However, rapid and direct non
carrier-added 18F-labeling of complex biomolecules such as peptides
is not straight forward. The main approach to label peptides with 18F
is via ﬂuorination of prosthetic groups which are then conjugated to
the biomolecule [22–24]. [18F]Galacto-RGD, a glycosylated cyclic
pentapeptide, is labeled via 18F-acylation with 4-nitrophenyl-2-[18F]
ﬂuoropropionate [25]. The acylation methodology is however com-
plex and time consuming. Synthesis of [18F]Galacto-RGD via this
prosthetic group method, requires a total synthesis time of about
200 min of which the production of the 18F-prosthetic group takes
about 130 min [25]. Another strategy, which has been applied for
the synthesis of [18F]AH111585, involves chemoselective oxime
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carbonyl group of the 18F-labeled aldehyde prosthetic group 4-[18F]
ﬂuorobenzaldehyde [26,27]. Introduction of ﬂuorine-18 can also be
achieved using the [18F]AlF method in which the ([Al18F]2+)-complex
is chelated to macrocyclic compounds like 1,4,7-triazacyclononane-
1,4,7-triacetic acid (NOTA) which can be stably attached to a peptide
[28]. For thermostable peptides, the labeling can be performed in one
step. Two steps are necessary for heat-labile proteins and peptides
where ﬁrst the binding ligand is labeled with Al18F at elevated
temperatures, which is then coupled to the protein [29]. Another
inorganic approach for labeling of biomolecules with ﬂuorine-18 is
the silicon-ﬂuoride acceptor (SiFA) labeling methodology which
uses silicon-containing prosthetic groups for the ﬂuorination of
peptides. To overcome the major problem of the in vivo instability of
the Si-18F bond, bulky alkyl groups need to be introduced in the
silicon-binding building block resulting in excessive lipophilicity
which in turn needs to be reduced by introduction of lipophilicity-
reducing auxiliaries [30].
Recently, the copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddi-
tion reaction (CuAAC) between terminal alkynes and azides resulting
in 1,4-disubstituted 1,2,3-triazoles [31,32] has found its way in
medicinal [33] and radiopharmaceutical chemistry [34]. The main
advantages of this ‘click chemistry’ approach are selectivity, reliability
and short reaction times under mild reaction conditions [35,36]. The
18F-labeling of peptides has been the area that has beneﬁted the most
from click chemistry [37,38]. The additional advantage of this
chemistry is that there is no need of protective groups when labeling
peptides. Both alkynes [37] and azides [38] have been radiolabeled
with ﬂuorine-18 to produce 18F-peptides.
As a result of a collaboration between the PET-centers in Leuven
(Belgium), Groningen (The Netherlands) and Siemens (MIBR, Los
Angeles, USA), we report an improved and simpliﬁed procedure to
prepare [18F]RGD-K5 using a Cu-catalyst based on the phosphorami-
dite ligand Monophos [39]. This paper describes in detail the
optimized radiosynthesis and QC procedure of [18F]RGD-K5, and
compares it with the registered method by Siemens [18–40]. The
efﬁcient radiosynthesis procedure can generally be applied for other
click reactions using [18F]ﬂuoroalkynes as prosthetic group.
2. Materials and methods
2.1. General
Reagents and solvents were obtained from commercial suppliers
(Aldrich, Fluka, Sigma, and Merck) and used without further
puriﬁcation. The RGD-K5 azide precursor and the authentic reference
material 19F-RGD-K5 (=‘cold’ standard) were prepared by Siemens.
For radiolabeled compounds, radioactivity detection on TLC was
performed with Cyclone phosphor storage screens (multisensitive,
PerkinElmer). These screens were exposed to the TLC strips and
subsequently read out using a Cyclone phosphor storage imager
(PerkinElmer, Netherlands) and analyzed with OptiQuant software.
HPLC analysis was performed on a LaChrom Elite Hitachi HPLC sys-
tem (Darmstadt, Germany) connected to a UV spectrometer (Waters
2487 Dual γ absorbance detector). For the analysis of radiolabeled
compounds, the HPLC eluate after passage through the UV detector
was led over a 3 in. NaI(Tl) scintillation detector (Wallac, Turku,
Finland) connected to a multi channel analyzer (Gabi box, Raytest,
Straubenhardt, Germany). The output signal was recorded and
analyzed using a GINA Star data acquisition system (Raytest,
Straubenhardt, Germany).
2.2. Production of 5-[18F]ﬂuoro-1-pentyne and [18F]RGD-K5
A solution of pent-4-ynyl-4-methylbenzenesulfonate (20–25 mg,
84–105 μmol) in 0.8-1 mL anhydrous 1,2-dichlorobenzenewas addedto the Kryptoﬁx 2.2.2 (20 mg)/K18F residue containing 5 mg of K2CO3
and the mixture was heated for 10 min at 110 °C to provide [18F]
ﬂuoropentyne which was simultaneously distilled with a gentle ﬂow
of helium to a second reactor containing the click reaction mixture.




1,4,7,10,13-pentaazacyclopentadecan-2-yl)acetic acid; TFA salt) in the
presence of 0.2 mg phosphoramidite Monophos (N,N-dimethyldi-
naphto[2,1-d: 1,2-f][1,3,2]dioxaphosphepin-4-amine) in 0.1 mL
DMSO, 1 mol% (0.05 mg) CuSO4.5H2O (reduced to Cu(I) with
5 mol% (0.25 mg) sodium ascorbate), in 0.25 mL EtOH and 0.25 mL
CH3CN (Table 1). The subsequent conversion to radiolabeled [18F]
RGD-K5 was followed by radio-TLC (Rf [18F]RGD-K5 = 0.4 (eluent:
MeOH/H2O 2:1)). After reacting at room temperature for 10 min, the
crude [18F]RGD-K5 was diluted with 1.5 mL of 0.025 M Na2HPO4 pH 7
and puriﬁed by semi-preparative RP-HPLC using an XBridge C18
column (5 μm, 4.6 mm × 150 mm column, Waters) eluted with
0.025M Na2HPO4 pH 7.0 and EtOH 88/12 at a ﬂow rate of 1 ml/min.
UV detection of the HPLC eluate was performed at 254 nm. [18F]RGD-
K5 was collected after 20–25 min (Fig. 2). On average, about 11 GBq
(n = 24, ranging from 3.7 to 19.5 GBq) of puriﬁed [18F]RGD-K5
was collected in a 1.3–2.6 mL volume (mobile phase). This HPLC-
puriﬁed fraction was diluted with preparative HPLC mobile phase
and passed through an apyrogenic 0.22 μmmembrane ﬁlter (Millex®-
GV, Millipore, Ireland). A ﬁnal solution of 370 MBq/mL was obtained
by further dilution with saline which was passed through the same
membrane ﬁlter.
2.3. Quality control procedures
Quality control procedures for [18F]RGD-K5 are based upon the
current requirements for radiopharmaceuticals laid out in the European
Pharmacopoeia [41]. A more detailed description on the materials and
methods of these QC tests can been previously described [42].
The radiochemical identity of [18F]RGD-K5 is checked using an
analytical HPLC system consisting of an XBridge C18 column (3.5 μm,
3 mm × 100 mm; Waters) eluted with 0.025 M Na2HPO4 (pH 7) and
CH3CN (90:10 v/v) at a ﬂow rate of 0.8 mL/min. UV detection of the
HPLC eluate is performed at 210 nm (Fig. 3). The radiochemical
identity of [18F]RGD-K5 is conﬁrmed using the 19F-RGD-K5 standard
as an external reference material. After injection and analysis of a
solution of the reference material RGD-K5, a blank injection of
preparative HPLC mobile phase is performed. The retention time of
[18F]RGD-K5 should be the same (±10%) as the retention time
observed for the RGD-K5 reference standard. The radiochemical
purity and speciﬁc activity are analyzed using the same HPLC system.
The total of radiolabeled side products should be ≤5%. Rather than
setting a lower limit for speciﬁc activity, the maximum mass of RGD-
K5 which is administered to a patient is limited to b96 μg and the
mass of the RGD-K5 azide precursor should be b5 μg per administered
dose, these limits were deﬁned in relation to toxicity tests ﬁndings
performed by Siemens. Residual solvent analysis is performed using
GC (direct injection). For the residual class 2 solvent acetonitrile a
limit of 4.1 mg per patient dose is set as described in the European
Pharmacopoeia. 1,2-Dichlorobenzene is not described in the European
Pharmacopoeia but has a no observed adverse effect level (NAOEL) of
120 mg/kg/day in rats which is considerably higher than for
chlorobenzene (27 mg/kg/day). For chlorobenzene the European
Pharmacopoeia sets a limit of 3.1 mg per day. In order to have a
safety margin we have therefore set a limit of 1 mg of o-DCB per
injected dose. To be safely administered to the patient, the amount of
residual ethanol should be b10% v/v. The drug product pH should be
in the range 5–8. Testing of the integrity of the ﬁlter that is used for
sterile ﬁltration is done by bubble point determination. The bubble
Table 1
Main differences in materials and methods between the optimized [18F]RGD-K5 production procedure as described in this article and the original Siemens protocol.
Optimized protocol Siemens protocol
Radiosynthesis of [18F]ﬂuoropentyne
Pentynyl tosylate 20–25 mg 20–25 mg
Solvent 1 mL o-DCB 0.8 mL CH3CN
Reaction temperature 110 °C 110 °C
Trapping of [18F]pentyne Room temperature −10 °C
Click reaction: radiosynthesis of [18F]RGD-K5
RGD-K5 azide 0.1 mg 4 mg
Na-ascorbate 0.25 mg 40 mg
CuSO4 0.05 mg 15 mg
Cu(I) Ligand 0.2 mg Monophos in 0.1 mL DMSO 15 mg TBTA
Solvent EtOH, CH3CN EtOH, water, CH3CN
Reaction temperature Room temperature Room temperature
HPLC puriﬁcation
Method Isocratic Stepwise gradient
Column XBridge C18 (5 μm,4.6 × 150 mm) Macherey-Nagel Nucleosil C18 (5 μm, 10 × 250 mm)
Mobile phase 0.025 M Na2HPO4 pH 7/EtOH Water/0.05% TFA 5′
88/12 v/v 5% CH3CN in water/0.05% TFA 5′
10% CH3CN in water/0.05% TFA 5′
18% CH3CN in water/0.05% TFA
Flow rate 1 mL/min 5 mL/min
Formulation Dilution to b10% EtOH C18 Sep Pak to remove CH3CN
QC
Method Isocratic Stepwise gradient
Column XBridge C18 (3.5 μm, 3 × 100 mm) Gemini C18 (5 μm, 4.6 × 150 mm)
Mobile phase 0.025 M Na2HPO4 pH 7/CH3CN Water/0.1% TFA
Flow rate 90/10 v/v CH3CN/0.1% TFA
0.8 mL/min 2 ml/min
Radiochemical yield (EOB) 35% 20%
Total synthesis time 70 min 90 min
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Determination of the radionuclide identity and endotoxin and
sterility testing are performed post batch release. Since CuSO4 is
being used in the manufacturing process of the radioligand, the
ﬁnished drug product should be tested for residual levels of the
metal reagent. This is done using inductively coupled plasma mass
spectrometry (ICP-MS).3. Result and discussion
Using our optimized click reaction condition we improved and
simpliﬁed the original registered Siemens production method.
Scheme 1 shows our optimized two-steps radiosynthetic route to
yield [18F]RGD-K5. In a ﬁrst step the labeling synthon 5-[18F]ﬂuoro-1-Scheme 1. A) Production of 5-[18F]ﬂuoro-1-pentyne: nucleophilic substitution between
MonoPhos Cu(I)-catalyzed Huisgen cycloaddition of [18F]ﬂuoropentyne with the RGD-K5 apentyne was prepared via nucleophilic ﬂuorination of pentynyltosy-
late with anhydrous [18F]KF-cryptate at 110 °C in o-DCB. The 18F-
labeled pentyne (Bp = 76 °C) was isolated from the tosyl precursor
and unreacted 18F- via distillation and was, without further
puriﬁcation, trapped in a receiving vial containing the RGD-K5 azide
precursor. Efﬂuent gasses that escaped from the receiving vial were
collected in a balloon. We choose a high boiling point solvent (o-DCB,
179 °C) instead of acetonitrile (82 °C), the solvent that was used by
Siemens, to prevent co-distillation of the solvent. Acetonitrile co-
distilling to the click reaction mixture was found to decrease the yield
of the click reaction and the efﬁciency of the HPLC puriﬁcation. The
distilled [18F]ﬂuoropentyne was efﬁciently trapped at room temper-
ature in the click reactor (90%). Radiometric detection showed that
the amount of [18F]ﬂuoropentyne in the receiving vial saturated after
about 10 min.pentynyl tosylate and anhydrous [18F]ﬂuoride in ortho-dichlorobenzene (o-DCB). B)
zide precursor resulting in the 1,4-disubstituted triazole [18F]RGD-K5.



















Fig. 1. Radiochemical conversion of the click reaction as a function of time and amount
of RGD-K5 azide precursor.
713L. Mirfeizi et al. / Nuclear Medicine and Biology 40 (2013) 710–716The phosphoramidite ligand Monophos showed to be an excellent
ligand for complexation of Cu(I) in order to catalyze the click
reaction [39] and is far superior to the previously reported ligand
TBTA which is used in the Siemens method [18,43]. Previously we
have shown in model systems that the Monophos approach
dramatically increased the radiochemical yield. Using 0.05–0.1 mg
amounts of benzyl azide conversion yields were 54–99% allowing 10
min for the click reaction. An amount of 0.2 mg Monophos proved to
be sufﬁcient to achieve these conversions [44]. In absence of the
Monophos ligand only minor conversion to the triazole product [18F]
RGD-K5 was observed. Further reaction optimization was performed
by varying the amount of RGD-K5 azide precursor from 0.1 mg to
2 mg (Fig. 1). By replacing the TBTA with 0.2 mg Monophos, the
amount of azide precursor could be reduced from 4 mg to 0.1 mg and
the amount of CuSO4 from 15 mg to 0.05 mg. So far 1 mol % of CuSO4
in the presence of 1.1 mol % Monophos showed sufﬁcient catalytic
effect within 15 min to produce [18F]RGD-K5 in an excellentFig. 2. Semi-preparative HPLC chromatogram of the puriﬁcation of [18F]RGD-K5. Upper chan
at 22 min. Unreacted [18F]ﬂuoropentyne elutes during rinsing of the column.radiochemical yield of 35% starting from only 0.1 mg azide precursor.
Usually, as in the Siemens method, large amounts of N1 mg peptide
are used without any additional catalysts beside Cu(I). As a result of
the dramatic acceleration of the click reaction by using Monophos, we
were able to produce [18F]RGD-K5 in good yield with substantially
less amount of the reactants sodium ascorbate, CuSO4 and azide
precursor (Table 1).
The crude click reaction mixture was puriﬁed using semi-
preparative HPLC. Before injection, the mixture was diluted with
phosphate buffer pH 7 to adjust the pH to that of the mobile phase
resulting in sharper peaks. We evaluated different sizes and types of
columns and found that the Waters XBridge C18 (5 μm,
4.6 mm × 150 mm) gave sharper peaks and provided the best
separation between the azide precursor and [18F]RGD-K5 (resolution
2.18). For the preparative HPLC puriﬁcation we preferred an isocratic
method with a mobile phase consisting of a phosphate buffer in
combination with ethanol instead of acetonitrile as was used by
Siemens. By using a mobile phase with ethanol as organic modiﬁer we
could eliminate the post HPLC SepPak formulation resulting in a
reduction of the synthesis time from 90 min (Siemens) to 75 min and
a more simple and reliable tracer production [45]. Using the XBridge
column in combination with a mobile phase consisting of 12% ethanol
in 0.025 M phosphate buffer pH 7, the unreacted azide precursor
eluted at 20 min and [18F]RGD-K5 at 25 min. The RGD-K5 azide
precursor and the reference compound RGD-K5 have their maximal
UV absorption at 210 nm. The reference compound also absorbs at
254 nm, the azide precursor does not. Since for the preparative
puriﬁcation UV detection was performed at 254 nm, the trace of
unreacted precursor is not visible in the UV channel of the preparative
HPLC chromatogram of the crude radiolabeling mixture (Fig. 2).
Within the isocratic conditions unreacted [18F]ﬂuoropentyne is
retained on the column and only elutes upon rinsing the HPLC column
with EtOH/H2O 70:30 v/v mixtures. The radiolabeled compound [18F]
RGD-K5 was obtained in 35% radiochemical yield based on [18F]
ﬂuoride starting radioactivity (decay-corrected) in 75 min.
Analysis of the radiochemical identity, radiochemical and chemical
purity and determination of speciﬁc radioactivity were performed onnel: radiometric detection. Lower channel: UV detection at 254 nm. [18F]RGD-K5 elutes
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3 × 100 mm) eluted with 0.025 M Na2HPO4 (pH7) and CH3CN (90:10
v/v). At a ﬂow rate of 0.8 mL/min, [18F]RGD-K5 eluted at 11 min. The
cold RGD-K5 standard eluted at the same retention time (11 min ±
1 min) conﬁrming the identity of the tracer. The radiochemical purity
was higher than 98% and the speciﬁc radioactivity of [18F]RGD-K5was
determined to be in the range of 100–200 GBq/μmol. The absolute
amount of cold RGD-K5 was in the range of 15–25 μg. For all
productions, QC HPLC analysis (Fig. 3) showed that the amount of
RGD-K5 azide precursor (Rt = 6 min) in the ﬁnal solution was lower
than the detection limit (LOD 0.2 ng), conﬁrming the efﬁcient
separation between the azide precursor and [18F]RGD-K5 with the
applied preparative HPLC system.
The concentration of copper was determined for 5 batches of [18F]
RGD-K5 and was found to be 53 ± 22 μg/L which corresponds to
1/10th of the concentration of naturally copper in plasma (50–150 μg/
dL) [46]. If the total batch would be injected into a single subject this
would result in the administration of b0.5 μg which corresponds to
less than 1/1000th of the daily recommended dose (1.2 mg/day),
indicating that there is a large safetymargin with regard to the copper
content in the [18F]RGD-K5 productions. Residual Kryptoﬁx-[2.2.2]
analysis was not performed as it was validated that Kryptoﬁx does
not co-distil with [18F]ﬂuoropentyne from the ﬁrst reaction vial. The
amount of acetonitrile and o-DCB in the ﬁnal formulation was below
the detection limit (LOD 0.0001%). Ethanol was present (b8%) to
increase radiochemical stability and to minimize the tracer being
retained on the walls of the sterile ﬁlter, the vial and the syringes used
to administer the drug product to the patient [45]. The pH of the ﬁnal
formulation was 7.
Radionuclide purity, sterility and endotoxin testing were per-
formed post batch release. The radionuclide identity was determined
using a two-time point radioactivity measurement in a dose-Fig. 3. Quality control of [18F]RGD-K5. Upper channel: UV detection at 210 nm. No trace of
channel: radiometric detection.calibrator. For all batches, the calculated half-life was in the range
105–115 min which is according to Ph.Eur. guidelines [41]. Bacterial
endotoxin determination of the [18F]RGD-K5 batches was done using
the Limulus amebocyte lysate (LAL) test according to the Ph.Eur.
guidelines [47]. For all batch productions the endotoxin content was
b1 IU/mL (limit set at 10 IU/mL). If the total batch volume (max
20 mL) would be injected to one volunteer the amount of injected IU
would be well below the 175 IU per dose limit for radiopharmaceu-
ticals speciﬁed in the Ph.Eur [47]. Sterility testing was done according
to Ph. Eur and no growth of microorganisms was detected after 14
days incubation at 37 °C in any of the batches [48].
By using the CuAAC Click reaction we were able to synthesize
[18F]RGD-K5 in good yield under very mild reaction conditions in a
reasonable time. By replacing the generally used Cu(I)-stabilizing
agents TBTA or diisopropylethyl amine (DiPEA) with Monophos, we
could signiﬁcantly reduce the amount of azide precursor and CuSO4
to ≤0.1 mg. Less precursor results in more efﬁcient preparative
HPLC puriﬁcation with less contamination of the drug product and
higher speciﬁc radioactivities. Although the decrease of the amount
of copper will already reduce the clinical concerns about metal
contamination of the radiopharmaceutical, future research should
also focus on the application of copper-free click chemistry for the
radiosynthesis of biomolecules. The recently developed [18F]AlF
method has the advantage that the chelation of the ﬂuoride can
be performed in aqueous medium circumventing the time consum-
ing dry-down step and that high speciﬁc activities can be obtained
after a simple solid phase extraction without chromatographic
puriﬁcation. However the ligand-peptide should be heated up to
100 °C to facilitate the formation of the Al18F-ligand bond, limiting
this method to peptides that can tolerate high temperatures. The
Monophos Cu(I) click coupling on the other hand can be performed
at room temperature, making this method applicable to bothRGD-K5 azide precursor is observed at the expected retention time of 6–7 min. Lower
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with metal-binding ligands is also applied for the radiolabeling of
peptides with gallium-68 [49]. This PET-radioisotope is readily
available at a reasonable cost from an in house 68Ge/68Ga generator
allowing production of these radiolabeled peptides in centers which
do not have an on-site cyclotron. Nevertheless, with 18F larger
radiotracer batches can be produced allowing more patient studies
to be performed per production. A disadvantage of the 68Ga is its
high maximum positron energy (1.9 MeV compared to 0.96 MeV
for 18F) limiting the spatial resolution of the images and increasing
the radiation dose to the patient. Although both the SiFA and the AlF
methodology tend more to be true-kit labeling procedures [29,50]
compared to the click chemistry approach, the metal-binding
ligands that need to be coupled to the peptide are large building
blocks, which may inﬂuence the molecular integrity, binding pro-
perties and immunoreactivity of the peptide or protein. The CuAAC
reaction requires less derivatization of the peptide. The triazole
linker can been seen as a surrogate for the amide bond and there-
fore adding a 1,2,3-triazole group is expected not to effect the
pharmacological properties of the resulting molecule.
Therefore click chemistry with 18F using the Monophos approach
results in a versatile production method for 18F-radiopharmaceuticals.
The use of very low amounts of reagents makes the method very
suitable if these radiopharmaceuticals are available in small quantities.4. Conclusion
[18F]RGD-K5 was synthesized with high speciﬁc activity and high
radiochemical yield using the monophos ligand accelerated Cu(I)-
catalyzed 1,3-dipolar cycloaddition reaction. The beneﬁcial effects of
this click chemistry for the synthesis of (radiolabeled) biomolecules
containing the RGD system will ensure the growth of this area in the
future. By applying Monophos as Cu(I) ligand, we were able to
optimize and simplify the Siemens method resulting in a shorter
synthesis time and a reduction of the amount of reagents. The QC
system has been validated and allows the tracer to be used in clinical
studies for visualization of neoangiogenesis in oncological patients in
our hospitals.References
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